Stage
Dead | DeadTotal Raised
$8.19MAbout LumeRx
LumeRx is a medical device company developing novel light-based therapies for the treatment of diseases caused by bacterial and other pathogenic infections. Its first device will deliver a specific wavelength of light to the stomach to eradicate h. pylori, the bacteria causing peptic ulcer disease (PUD) and believed to be the cause of gastric cancer.
LumeRx Headquarter Location
100 Locke Drive
Marlborough, Massachusetts, 01752,
United States
508-787-9811
Latest LumeRx News
Aug 7, 2017
May, 2008 - LumeRx reported several events concerning its plans moving forward. Trial results analysis from work recently completed in India reveals current visible light approaches are not adequate as a primary treatment for H. Pylori. As a result of these findings, the Company's investors have decided to not invest further in LumeRx and to scale back operations. Jon McGrath has stepped down from his position as CEO with day-to-day responsibilities assumed by David Hendren of Catalyst Health Ventures. Catalyst and other investors are now considering the future course for the LumeRx. http://www.masshightech.com/stories/2008/05/26/weekly13-Future-is-unclear-as-LumeRx-shuffles-execs,-Gabrieli-ends-funding.html Posted by
Expert Collections containing LumeRx
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
LumeRx is included in 2 Expert Collections, including Smart Money VCs (2017-2019).
Smart Money VCs (2017-2019)
6,297 items
We crunched the data to identify the 24 VC firms with the best combination of portfolio valuations and investment outcomes.
Cancer
4,844 items
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.